{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001637433,0.0005385301,0.002782019,0.000368302,0.0001399998,0.00003040523,0.0002783897,0.00007535746,0.0002983999],"category_scores_gemma":[0.0001984554,0.0002488737,0.0001624124,0.001277117,0.0009329398,0.0003297587,0.00005179965,0.0003778697,0.000007260314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002084187,"about_ca_system_score_gemma":0.0003142217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003258374,"about_ca_topic_score_gemma":0.01761851,"domain_scores_codex":[0.9954724,0.001562737,0.001007919,0.0007344231,0.0005777818,0.0006447301],"domain_scores_gemma":[0.995349,0.002872747,0.0007854419,0.0005480141,0.0002682832,0.0001764918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.922018,0.00410069,0.01005934,0.00001070193,0.005557809,0.0001590918,0.008550045,0.0008919238,0.002119895,0.00001275703,0.000001942788,0.04651782],"study_design_scores_gemma":[0.8678102,0.00320548,0.1114971,0.0003666551,0.002477429,0.00001269116,0.01316927,0.0007200459,0.0002259359,0.0001513913,0.00001107496,0.0003526542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820181,0.0004904721,0.005325763,0.003071016,0.00004696229,0.008514379,0.0003606701,0.00007728184,0.00009541795],"genre_scores_gemma":[0.9925421,0.0004480006,0.001485648,0.0002197664,0.00004035548,0.004999788,0.00003646436,0.00005300854,0.0001748175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1014378,"threshold_uncertainty_score":0.9999964,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009780463777112593,"score_gpt":0.2961600474988715,"score_spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}